AMH Test

The AMH test measures anti-Mullerian hormone in a blood sample. Ovarian follicles produce this hormone, so the result can provide information about the remaining pool of follicles, often called ovarian reserve. It is one piece of a fertility assessment, alongside menstrual history, age, ultrasound findings, and other tests.

A clinician or phlebotomist takes a blood sample from a vein in your arm. The sample is sent to a laboratory, which measures AMH and returns a result for your clinician to interpret. Ask whether you need to avoid food, change medicines, or arrange the test at a particular point in your cycle; preparation can depend on the clinic and your wider assessment.

The test uses a routine blood draw. You may have brief discomfort, bruising, light-headedness, or bleeding at the puncture site. AMH is useful information, but it is not a direct count of eggs and cannot by itself diagnose infertility or predict pregnancy. Results can vary with the laboratory method, hormonal medicines, and certain medical conditions, so interpretation belongs with the rest of your history.

A result outside the expected range does not give a diagnosis on its own. A lower result may lead the clinician to discuss ovarian reserve and treatment planning; a higher result may be considered with symptoms, ultrasound, or a possible polycystic ovary pattern. Your clinician may recommend repeat or additional assessment rather than making a decision from AMH alone. Discuss how the result relates to [Diminished Ovarian Reserve](/conditions/diminished-ovarian-reserve/) or [Female Infertility](/conditions/female-infertility/).

AMH helps estimate follicle activity, not egg quality. A result cannot confirm whether you can or cannot conceive naturally. It may help a fertility team plan how closely to monitor response if treatment such as [Ovarian Stimulation](/treatments/fertility-and-assisted-reproduction/ovarian-stimulation/) is being considered.

A clinician may request AMH during fertility assessment, before some assisted-reproduction plans, or when ovarian function needs further evaluation. It may also be discussed when menstrual or ultrasound findings raise a question about ovarian reserve. The reason for testing should be clear before the sample is taken.

The visit usually follows this sequence: review your medicines and reason for testing; clean the skin; collect blood from an arm vein; label and send the sample; then arrange a results discussion. Keep the dressing on for the period advised by the person taking the sample and report persistent bleeding or worsening swelling.

Most people return to ordinary activities after the blood draw. Mild soreness or a small bruise can occur around the puncture site. Results are available after the laboratory has processed the sample, and your clinic should tell you when and how they will be discussed.

The main risks are those of venous blood collection, such as bruising, faintness, or a small amount of bleeding. Tell the clinician if you have previously fainted during blood tests or take medicines that affect clotting. The larger clinical risk is misunderstanding the result, especially treating it as a stand-alone fertility forecast.

Depending on the question, assessment may include antral follicle count by ultrasound, follicle-stimulating hormone testing, cycle history, semen analysis for a partner, or other fertility investigations. These tests answer different questions and may be combined rather than substituted one-for-one.

Choose a clinician or fertility service that can explain why AMH is being ordered, which laboratory performs it, and how the result will affect the plan. Before your appointment, bring a list of medicines and previous fertility or ultrasound results. Request a clear explanation of the result range used by that laboratory.